No male birth control pill is available yet. As of 2025, condoms and vasectomies remain the only contraceptive options for men approved by regulators. But several experimental pills are in clinical trials, and the closest candidates could reach the market before 2030 if development stays on track.
Why It Has Taken So Long
Female oral contraceptives have been on the market since the 1960s, so the gap feels enormous. The delay comes down to biology. Sperm production happens behind what’s called the blood-testis barrier, one of the tightest protective barriers in the human body. It works like a biological security gate: specialized cells form a seal around the tubes where sperm develop, and drug-pumping proteins actively push foreign substances back out. Any pill that needs to act directly on developing sperm has to get past this barrier in high enough concentrations to work, which has been an engineering problem for over a century.
There’s also a numbers problem. Women release one egg per month. Men produce roughly 1,000 sperm per second. Suppressing that volume of production reliably, safely, and reversibly is a much harder pharmacological target. And unlike female contraceptives, which had military and government funding driving early development, male contraceptive research has been chronically underfunded by pharmaceutical companies skeptical of market demand.
The Non-Hormonal Pill: YCT-529
The most talked-about candidate is YCT-529, developed by YourChoice Therapeutics. It’s the first non-hormonal male contraceptive pill to reach human clinical trials. The pill works by blocking a protein that’s essential for sperm production. Without that protein’s activity, the testes can’t complete the process of building mature sperm cells.
In animal studies, the results were striking. Mice given the drug daily for four weeks had a 99% contraception rate in mating studies, and fertility returned completely within six weeks of stopping the drug. In rats, sperm concentrations dropped by roughly 75% at the lowest effective dose. The drug stayed active in the body for 10 to 13 hours per dose without building up over time, and it was well tolerated at doses 40 times higher than the effective amount.
The phase 1 human trial, completed recently, confirmed the pill is safe. It did not, however, test whether it actually lowers sperm counts in men. Those efficacy trials are currently underway. The developer expects the final dose to land around 180 mg daily, though follow-up trials will narrow that down. If everything proceeds smoothly, FDA approval is still years away, likely requiring phase 2 and phase 3 trials before a final decision.
Hormonal Pills in Development
A separate line of research uses hormones to shut down sperm production, similar in concept to how female birth control pills work. These pills deliver a synthetic compound that mimics the effects of testosterone and progesterone, tricking the brain into dialing down the hormonal signals that drive sperm production.
The furthest along is dimethandrolone undecanoate, or DMAU. In a 28-day trial of 100 men, the 400 mg dose suppressed reproductive hormones to levels low enough to halt sperm production in nearly all participants (92 to 100%, depending on formulation). There were no serious adverse events, but side effects included decreased sex drive in about 25% of men at the highest dose, along with some weight gain and a drop in HDL (“good”) cholesterol of 6 to 15 mg/dL. About 13% of men on the highest dose reported erectile difficulty. These side effects echo some of the concerns that have historically slowed male hormonal contraceptive research, though supporters note they’re comparable to what women experience on their own hormonal birth control.
A related compound called 11β-MNTDC works through a similar mechanism and is also in early trials. Both drugs are testosterone derivatives that don’t convert to estrogen in the body, which helps avoid certain unwanted effects. Neither has reached the stage of large-scale efficacy testing in humans.
The Gel That May Arrive First
The male contraceptive closest to market isn’t actually a pill. It’s a daily gel called NES/T that combines a synthetic progestin with testosterone, applied to the shoulders. The progestin suppresses the hormonal signals needed for sperm production, while the testosterone component prevents symptoms of low testosterone like fatigue, mood changes, and loss of muscle mass.
In phase 1 trials, the gel suppressed sperm production in nearly 90% of participants. A larger phase 2 trial has been completed, and researchers hope to begin phase 3 testing soon. If current timelines hold, experts in reproductive medicine project that hormonal male contraceptives like this gel could reach the market before 2030. Bringing a new drug to market takes an average of 10 years from early development, so the gel’s head start matters.
How Effective Would a Male Pill Be?
Female birth control pills are about 91% effective with typical use (accounting for missed doses and human error) and over 99% effective with perfect use. Male contraceptive candidates are aiming for similar numbers. A large injectable hormone trial previously demonstrated 96% effectiveness in preventing pregnancy among participants’ partners, setting a benchmark that pill developers are targeting.
The non-hormonal approach (YCT-529) achieved 99% effectiveness in mouse mating studies, but translating animal results to humans is never straightforward. Real-world efficacy data in men won’t be available until phase 2 and 3 trials wrap up.
Reversibility: Will Fertility Come Back?
This is one of the first questions men ask, and the early data is reassuring across the board. In animal studies of YCT-529, full fertility returned six weeks after stopping the drug. The hormonal candidates also show reversibility: because they work by suppressing the brain’s signals to the testes rather than damaging the reproductive system, sperm production restarts once the drug clears. In hormonal trials with women, this same principle has held true for decades.
The timeline for recovery will vary by drug. Hormonal approaches that suppress sperm production over months may take longer to bounce back (roughly 3 to 4 months based on earlier injectable trials) compared to non-hormonal pills that block a single step in sperm development. One experimental compound tested at NIH worked so quickly and wore off so fast that fertility in mice returned within 24 hours, though that particular drug is designed more as an on-demand option than a daily pill.
A Realistic Timeline
If you’re hoping to pick up a male birth control pill at the pharmacy next year, that’s not happening. The most optimistic expert estimates place the first approved male contraceptive (likely the NES/T gel, not a pill) on the market before 2030. A non-hormonal pill like YCT-529 is further behind, still working through early-stage trials that need to prove the drug actually reduces sperm counts in humans before larger efficacy studies can begin.
For now, the realistic options remain condoms and vasectomies. But the pipeline is more active than it has ever been, with multiple candidates using fundamentally different approaches all moving through human trials simultaneously. The question has shifted from “is this possible” to “which one will cross the finish line first.”